This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 3.26% and 0.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
by Zacks Equity Research
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
by Kinjel Shah
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
An Uneasy Calm and 2025 Outlooks: Global Week Ahead
by John Blank
An uneasy calm has descended on investors, hopeful that the worst of the tariff-induced turmoil has passed. Wall Street shares have recovered from more than one-year lows, but are sinking again early this week.
Strength Seen in Lilly (LLY): Can Its 14.3% Jump Turn into More Strength?
by Zacks Equity Research
Lilly (LLY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ahead of Merck (MRK) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Merck (MRK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Johnson & Johnson (JNJ) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.78% and 1.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Merck and AbbVie
by Zacks Equity Research
Merck and AbbVie are included in this Analyst Blog.
Merck (MRK) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $79.17, representing a -0.01% change from its previous close.
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
by Kinjel Shah
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
Here's Why Summit Therapeutics Stock Soared 15% on Friday
by Zacks Equity Research
The surge in SMMT's share price comes after some established investment firms maintain their positive outlook on the company, citing optimism around its lead pipeline drug.
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
by Sundeep Ganoria
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Merck (MRK) Stock Moves -0.24%: What You Should Know
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $86.39, representing a -0.24% change from its previous close.
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
by Kinjel Shah
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The Zacks Analyst Blog Highlights Amazon.com, Oracle and Merck
by Zacks Equity Research
Amazon.com, Oracle and Merck are part of the Zacks top Analyst Blog.
Top Analyst Reports for Amazon, Oracle & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Oracle Corp. (ORCL) and Merck & Co., Inc. (MRK).
Why the Market Dipped But Merck (MRK) Gained Today
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $89.23, denoting a +1.86% change from the preceding trading day.
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
by Zacks Equity Research
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.